ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that significant clinical data for its structural heart portfolio is being presented during EuroPCR. Among the highlights are first-in-man and six-month data for the company’s Portico™ Transcatheter Aortic Heart Valve and results from a multicenter study for AMPLATZER™ Cardiac Plug (ACP) technology.
